Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system - IMAG Accéder directement au contenu
Article Dans Une Revue Therapeutic advances in musculoskeletal disease Année : 2021

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

Résumé

Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of such treatment has to take into account the patient’s comorbidities. Neurologic diseases are common and their association with SpA deserves to be studied. Therefore, the role of TNF-α and IL-17 cytokines is worth investigating in these neuropsychiatric diseases. This review aimed to explore the role of TNF-α and IL-17 in the pathogenesis of uveitis, multiple sclerosis, neuromyelitis optica, Alzheimer’s disease, Parkinson’s disease and depression. This update is critical to guide the therapeutic management of these co-morbidities in SpA patients.
Fichier principal
Vignette du fichier
1759720x211025894.pdf (175.19 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03652850 , version 1 (27-04-2022)

Licence

Paternité

Identifiants

Citer

Elsa How Shing Koy, Pierre Labauge, Athan Baillet, Clément Prati, Hubert Marotte, et al.. Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system. Therapeutic advances in musculoskeletal disease, 2021, 13, pp.1759720X2110258. ⟨10.1177/1759720X211025894⟩. ⟨hal-03652850⟩
421 Consultations
52 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More